Sean Christensen, Dexcom's vice president of investor relations, discussed the rationale for launching an OTC device at the Raymond James Institutional Investors Conference on Tuesday. Christensen said Dexcom has seen "an uptick in CGM starts once people start on GLP-1 therapy," creating "a little bit of a tailwind" for the company as demand for Eli Lilly's Mounjaro and Novo Nordisk's Ozempic has taken off.